FOXP3在BRCA1/2突变乳腺癌中的表达及临床意义

Clinical Significance of FOXP3 Expression in BRCA1/2-Mutant Breast Cancer

目的探讨BRCA1/2突变乳腺癌FOXP3表达情况及潜在意义。方法选取北京大学肿瘤医院48例BRCA突变者(BRCA116例,BRCA232例)和78例年龄匹配的非突变者,采用免疫组织化学检测乳腺癌组织FOXP3的表达情况。为验证免疫组织化学结果,分析TCGA-BRCA中39例BRCA1、36例BRCA2和948例非携带者乳腺癌的FOXP3 RNA表达水平及其与同源重组缺陷评分的关系。结果在BRCA1突变者中FOXP3阳性率43.8%(7/16),BRCA2突变者为59.4%(19/32),非携带者为9.0%(7/78)。BRCA1/2突变患者FOXP3阳性率均显著高于非突变者(P=0.002;P<0.001)。TCGA-BRCA结果显示,BRCA1/2突变乳腺癌的FOXP3 RNA水平也显著高于非携带者(P=0.02,P=0.004)。FOXP3 RNA水平与同源重组缺陷评分正相关(Spearman R=0.30,P<2.2e-16)。结论BRCA1/2突变乳腺癌较非突变者FOXP3表达更高,可能对免疫治疗更敏感。

Objective To investigate the potential significance of FOXP3 expression in BRCA1/2-mutant breast cancer.Methods A total of 48 BRCA mutation carriers(16 with BRCA1 and 32 with BRCA2)and 78 age-matched non-carriers were included in this study.Immunohistochemistry was used to detect the expression of FOXP3 in breast cancer tissues.The FOXP3 RNA expression in 39 BRCA1,36 BRCA2,and 948 non-carrier breast cancer patients from TCGA-BRCA and the correlation with homologous recombination deficiency scores were evaluated to validate the immunohistochemistry results.Results The FOXP3 positive rate was 43.8%(7/16)in BRCA1 mutation carriers,59.4%(19/32)in BRCA2 mutation carriers,and 9.0%(7/78)in non-carriers.The FOXP3 positive rates in patients with BRCA1/2 mutant breast cancer were significantly higher than those in non-carriers(P=0.002;P<0.001).TCGA-BRCA results showed that the FOXP3 RNA level in BRCA1/2 mutant breast cancer was significantly higher than that in non-carriers(P=0.02,P=0.004).The FOXP3 RNA level was positively correlated with the homologous recombination deficiency score(Spearman R=0.30,P<2.2e-16).Conclusion Patients with BRCA1/2 mutant breast cancers have higher FOXP3 expression than non-carriers,and may be more sensitive to immunotherapy.